Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Rhea-AI Summary

Daré Bioscience (NASDAQ:DARE) announced that President and CEO Sabrina Martucci Johnson will speak at multiple events and deliver a corporate presentation during the BIO International Convention 2026 in San Diego from June 22-25.

Sessions will cover women's health innovation, leadership, mentorship, and clinical development pathways.

News Market Reaction – DARE

+4.33%

+4.33% Session close to close

In the Jun 18 session, DARE gained 4.33%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands Daré’s visibility at BIO 2026, showcasing its women’s health portfolio and...

Analysis

This announcement expands Daré’s visibility at BIO 2026, showcasing its women’s health portfolio and upcoming milestones. With recent financing activity and going-concern disclosures, investors may watch how partnering or interest from these meetings supports future funding paths.

Key Figures

Q1 2026 net loss: $3.0 million Q1 2025 net loss: $4.4 million Q1 2026 revenue: $152,455 +5 more

8 metrics

Q1 2026 net loss $3.0 million Quarter ended March 31, 2026

Q1 2025 net loss $4.4 million Prior-year quarter comparison

Q1 2026 revenue $152,455 Research and development services and royalties

Cash and equivalents $18.5 million Balance as of March 31, 2026

Working capital $0.5 million As of March 31, 2026, mostly restricted cash

Reg A units issued 195,010 units at $5.00 Regulation A offering closings on May 1–6, 2026

Additional Reg A units 50,000 units at $5.00 Additional Regulation A unit offering closing

ARPA-H program funding $10 million Program supporting DARE-HPV development

Historical Context

5 past events · Latest: Jun 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 04	Product launch update	Positive	+6.3%	Announced upcoming U.S. launch of Flora Sync LF5 and first direct revenue.
May 26	Grant funding award	Positive	-1.3%	Received second $1.0M NIH SBIR tranche, bringing DARE-HPV funding to $2.0M.
May 18	Phase 2 initiation	Positive	-2.8%	Initiated ARPA-H–funded Phase 2 study of DARE-HPV for high-risk HPV.
May 14	Earnings and update	Negative	-24.1%	Reported Q1 2026 loss and outlined milestones amid funding and going-concern risks.
May 12	Interim Phase 3 data	Positive	+4.4%	Released positive interim Phase 3 Ovaprene results with continued DSMB support.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

DARE often reacts in line with news tone, though recent positive development and funding updates have twice coincided with negative price moves.

Key Terms

regulation a, series a convertible preferred stock, investor warrants, going concern, +1 more

5 terms

regulation a regulatory

"raising funds through a Regulation A preferred/warrant offering and an equity line"

Regulation A is a U.S. securities rule that lets smaller or growing companies offer shares to the public with simpler paperwork and lower costs than a full stock market listing, acting as a middle ground between private fundraising and a traditional public offering. For investors it matters because it opens access to early-stage opportunities that would otherwise be private, but these offerings can carry higher risk and different disclosure standards than large, fully listed companies.

series a convertible preferred stock financial

"each priced at $5.00, with each unit consisting of one share of Series A Convertible Preferred Stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

investor warrants financial

"each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants"

Investor warrants are tradable rights that let the holder buy a company’s stock at a fixed price for a limited time. They matter because they can amplify returns if the share price rises above that fixed price, but they also can dilute existing shareholders if exercised; think of a warrant as a coupon that lets you purchase shares later at today’s price, creating potential upside for the holder and a future change in share count for investors.

going concern financial

"Management states there is substantial doubt about its ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

phase 3 medical

"A Phase 3 trial of Ovaprene with a second positive DSMB review"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that President and Chief Executive Officer, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a Company corporate presentation during the BIO International Convention 2026, taking place June 22-25 in San Diego, California.

As one of the biotechnology industry's premier global gatherings, BIO International Convention brings together thousands of executives, investors, innovators, policymakers and strategic partners to shape the future of healthcare. Daré's participation underscores the Company's growing leadership role in advancing innovation for women and accelerating the development of solutions that have historically been underrepresented in healthcare.

"Women's health represents one of the largest and most underserved opportunities in healthcare today," said Ms. Johnson. "BIO International Convention provides an exceptional platform to engage with global industry leaders, investors and potential collaborators who share a commitment to advancing innovation and improving health outcomes. We are excited to highlight Daré's progress and discuss how our differentiated portfolio is positioned to address significant unmet needs while creating meaningful value for patients, partners and shareholders."

Details of the Company’s participation at BIO International Convention 2026 are as follows:

Invest in San Diego Breakfast
Date: Monday, June 22, 2026
Time: 7:30 – 9:30 a.m. PT
Location: IQHQ, 975 Waterfront Place, San Diego, California

Ms. Johnson will participate as a featured speaker during the breakfast program, which highlights the San Diego region's life sciences ecosystem and brings together biotechnology executives, investors and industry stakeholders.

WIB@BIO 2026 Executive Breakfast: Sparking Greatness — Leading Through Inspiration
Date: Monday, June 22, 2026
Time: 9:00 – 11:00 a.m. PT
Location: RaDD (IQHQ), 6th Floor, 925 Waterfront Place, San Diego, California

Ms. Johnson will join fellow biotechnology leaders for a discussion focused on leadership, mentorship and fostering innovation across the industry.

BIO International Convention Corporate Presentation
Date: Tuesday, June 23, 2026
Time: 3:30 p.m. PT
Location: Theater 4

Ms. Johnson will discuss Daré Bioscience's corporate strategy, commercial and development portfolio and upcoming milestones, highlighting the Company's commitment to delivering impactful solutions that seek to address critical gaps in women's healthcare.

Are We There Yet: The Road to Clinical Development in Women's Health
Date: Wednesday, June 24, 2026
Time: 4:15 – 5:15 p.m. PT
Location: Room 26AB

Ms. Johnson will join industry leaders and women's health advocates for a discussion examining the challenges and opportunities in advancing clinical development for women's health products. The session will explore pathways to accelerate innovation, improve patient access and address longstanding gaps in women's healthcare research and development.

Investors and conference attendees interested in meeting with Daré management during the BIO International Convention are encouraged to contact the Company to arrange a meeting. For more information, please visit the convention website.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs. For decades, women have been told to "wait it out" or "live with it," while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré is working to change that. Learn more at darebioscience.com.

CONTACT:
Daré Bioscience Investor Relations
innovations@darebioscience.com

FAQ

What is Daré Bioscience (NASDAQ:DARE) doing at BIO International Convention 2026?

Daré Bioscience is participating in several speaking engagements and a corporate presentation at BIO International Convention 2026. According to Daré Bioscience, CEO Sabrina Martucci Johnson will discuss women’s health innovation, corporate strategy, development portfolio, and upcoming milestones across multiple sessions in San Diego.

When and where is Daré Bioscience presenting its corporate strategy at BIO 2026?

Daré Bioscience will present its corporate strategy on Tuesday, June 23, 2026, at 3:30 p.m. PT in Theater 4. According to Daré Bioscience, the session will cover commercial and development portfolios and upcoming milestones in women’s health.

Which panels will Daré Bioscience’s CEO join at BIO International Convention 2026?

Sabrina Martucci Johnson will speak at the Invest in San Diego Breakfast, the WIB@BIO 2026 Executive Breakfast, and a clinical development panel. According to Daré Bioscience, these sessions focus on leadership, mentorship, innovation, and advancing clinical development in women’s health.

What is the focus of the women’s health clinical development panel featuring Daré Bioscience at BIO 2026?

The panel “Are We There Yet: The Road to Clinical Development in Women's Health” will examine challenges and opportunities in women’s health trials. According to Daré Bioscience, it will explore ways to accelerate innovation, improve patient access, and address research gaps.

How can investors meet Daré Bioscience management during BIO International Convention 2026?

Investors can request meetings with Daré Bioscience management during BIO International Convention 2026. According to Daré Bioscience, interested investors and attendees are encouraged to contact the company directly and may visit the convention website for additional logistical information.